Get Your Personalized Supplement StackSupplement Stack Quiz

Akkermansia

Also known as: Akkermansia muciniphila, A. muciniphila, Akkermansia

Overview

Akkermansia muciniphila is a mucin-degrading, anaerobic bacterium naturally found in the human gut microbiota, particularly in the mucus layer of the colon. It is being investigated for its potential benefits in metabolic health, gut barrier integrity, anti-inflammatory effects, and potential roles in aging and neurodegenerative diseases. This bacterium utilizes mucin as a primary energy source, produces short-chain fatty acids (SCFAs), and modulates host immune responses. Research is in the early to mid-stage, with preclinical and small human trials predominating, and increasing interest in large-scale studies. The quality of available evidence is moderate to high for preclinical and mechanistic studies, but emerging and limited for large, long-term human randomized controlled trials (RCTs). Both live and pasteurized forms are being studied.

Benefits

Akkermansia muciniphila supplementation has shown potential benefits, particularly in metabolic health. In overweight or obese, insulin-resistant individuals, studies have shown improvements in insulin sensitivity, reduced insulinemia, and lowered plasma cholesterol, although no significant changes in body weight or fat mass were observed. It also strengthens the intestinal barrier, reducing systemic inflammation and the risk of metabolic endotoxemia. Meta-analyses and systematic reviews suggest a negative association between Akkermansia and type 2 diabetes, with improved postprandial glucose control in human trials. Emerging evidence suggests anti-inflammatory, potential anti-aging, and neuroprotective effects, although these are less well-established in humans. Most evidence is concentrated in overweight/obese, insulin-resistant, or type 2 diabetes populations.

How it works

Akkermansia muciniphila enhances gut barrier function by utilizing mucin, a major component of the gut's mucus layer. This process promotes the production of short-chain fatty acids (SCFAs), which are beneficial for gut health and overall metabolism. It also modulates immune responses in the gut, helping to maintain a balanced immune environment. Furthermore, Akkermansia can competitively exclude pathogenic bacteria, contributing to a healthier gut microbiome. These actions influence the gut–liver–brain axis, impacting metabolic, immune, and neurological health. Molecular targets include mucin glycoproteins, toll-like receptors, and GLP-1 secretion pathways.

Side effects

Akkermansia muciniphila is generally well-tolerated in clinical trials, with no serious adverse events reported in human studies. The most common side effects are mild gastrointestinal symptoms, such as bloating and flatulence, which occur in a minority of participants. Uncommon side effects are not well-documented but are likely similar to those associated with other probiotics. No rare side effects have been reported in published trials. There are no significant drug interactions reported, although a theoretical risk exists with immunosuppressants, but there is no clinical evidence to support this. There are no established contraindications, but caution is advised in immunocompromised individuals, as with all live probiotics. Safety in pregnancy, children, and the elderly is not well-studied, so use with caution in these groups.

Dosage

The minimum effective dose of Akkermansia muciniphila is not firmly established, but human trials have used dosages ranging from 10^9 to 10^10 CFU/day. The optimal dosage range is generally considered to be between 10^9 and 10^10 CFU/day, typically administered as a single daily dose. The maximum safe dose has not been definitively determined, but doses up to 10^10 CFU/day appear to be safe in short-term studies. It is typically administered with or without food, and the optimal timing has not been established. Both live and pasteurized forms have demonstrated efficacy, with some studies suggesting that the pasteurized form may offer superior metabolic benefits. It acts locally in the gut, and systemic absorption is not required for efficacy. No specific cofactors have been identified, but the benefits may be enhanced by prebiotic fibers that support mucin production.

FAQs

When is the best time to take Akkermansia?

Akkermansia can be taken with or without food. The timing relative to meals is not critical, so choose a time that is convenient for you to ensure consistent daily intake.

Is Akkermansia safe for everyone?

Akkermansia is generally safe for healthy adults. However, individuals who are immunocompromised should avoid it until more data are available due to the potential risks associated with live probiotics.

What are the expected benefits of taking Akkermansia?

You may experience improvements in metabolic markers such as insulin sensitivity and cholesterol levels within a few weeks. However, it is important to note that weight loss is not a consistently observed outcome.

Is Akkermansia a weight loss supplement?

No, Akkermansia is not primarily a weight loss supplement. Its main benefits are related to metabolic and anti-inflammatory effects, rather than direct weight reduction.

Are live or pasteurized forms better?

Both live and pasteurized forms have shown efficacy. Some studies suggest the pasteurized form may offer superior metabolic benefits, but more research is needed to confirm these findings.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC9959343/ – This review discusses the potential of Akkermansia muciniphila as a therapeutic agent for various health conditions. It highlights the bacterium's role in modulating gut microbiota composition and function, as well as its impact on host immunity and metabolism. The review also addresses the challenges and future directions in translating Akkermansia-based therapies to clinical practice.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9135416/ – This review examines the role of Akkermansia muciniphila in human health and disease. It summarizes the current understanding of the bacterium's mechanisms of action, including its ability to degrade mucin, produce short-chain fatty acids, and modulate immune responses. The review also discusses the potential therapeutic applications of Akkermansia in metabolic disorders, inflammatory bowel disease, and cancer.
https://www.mdpi.com/2072-6643/16/20/3440 – This study investigates the effects of Akkermansia muciniphila supplementation on metabolic parameters in overweight and obese individuals. The results showed that Akkermansia supplementation improved insulin sensitivity, reduced insulinemia, and lowered plasma cholesterol levels. However, it did not significantly affect body weight or fat mass, suggesting that Akkermansia may have beneficial effects on metabolic health independent of weight loss.
https://www.tandfonline.com/doi/full/10.1080/21505594.2024.2375555 – This systematic review analyzes the association between Akkermansia muciniphila and metabolic diseases. The review found that Akkermansia is negatively associated with metabolic diseases, strengthens the gut barrier, and has anti-inflammatory effects. However, the authors note that more high-quality human studies are needed to confirm these findings and elucidate the underlying mechanisms.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1484656/full – This article discusses the potential of Akkermansia muciniphila as a next-generation probiotic for various health conditions. It highlights the bacterium's role in modulating gut microbiota composition and function, as well as its impact on host immunity and metabolism. The review also addresses the challenges and future directions in translating Akkermansia-based therapies to clinical practice.